RESUMEN
MOTIVATION: Gene fusions resulting from chromosomal aberrations are an important cause of cancer. The complexity of genomic changes in certain cancer types has hampered the identification of gene fusions by molecular cytogenetic methods, especially in carcinomas. This is changing with the advent of next-generation sequencing, which is detecting a substantial number of new fusion transcripts in individual cancer genomes. However, this poses the challenge of identifying those fusions with greater oncogenic potential amid a background of 'passenger' fusion sequences. RESULTS: In the present work, we have used some recently identified genomic hallmarks of oncogenic fusion genes to develop a pipeline for the classification of fusion sequences, namely, Oncofuse. The pipeline predicts the oncogenic potential of novel fusion genes, calculating the probability that a fusion sequence behaves as 'driver' of the oncogenic process based on features present in known oncogenic fusions. Cross-validation and extensive validation tests on independent datasets suggest a robust behavior with good precision and recall rates. We believe that Oncofuse could become a useful tool to guide experimental validation studies of novel fusion sequences found during next-generation sequencing analysis of cancer transcriptomes. AVAILABILITY AND IMPLEMENTATION: Oncofuse is a naive Bayes Network Classifier trained and tested using Weka machine learning package. The pipeline is executed by running a Java/Groovy script, available for download at www.unav.es/genetica/oncofuse.html.
Asunto(s)
Fusión Génica , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Neoplasias/genética , Oncogenes , Teorema de Bayes , Bases de Datos Genéticas , Perfilación de la Expresión Génica , Genómica , HumanosRESUMEN
Reciprocal chromosomal translocations (RCTs) leading to the formation of fusion genes are important drivers of hematological cancers. Although the general requirements for breakage and fusion are fairly well understood, quantitative support for a general mechanism of RCT formation is still lacking. The aim of this paper is to analyze available high-throughput datasets with computational and robust statistical methods, in order to identify genomic hallmarks of translocation partner genes (TPGs). Our results show that fusion genes are generally overexpressed due to increased promoter activity of 5' TPGs and to more stable 3'-UTR regions of 3' TPGs. Furthermore, expression profiling of 5' TPGs and of interaction partners of 3' TPGs indicates that these features can help to explain tissue specificity of hematological translocations. Analysis of protein domains retained in fusion proteins shows that the co-occurrence of specific domain combinations is non-random and that distinct functional classes of fusion proteins tend to be associated with different components of the gene fusion network. This indicates that the configuration of fusion proteins plays an important role in determining which 5' and 3' TPGs will combine in specific fusion genes. It is generally accepted that chromosomal proximity in the nucleus can explain the specific pairing of 5' and 3' TPGS and the recurrence of hematological translocations. Using recently available data for chromosomal contact probabilities (Hi-C) we show that TPGs are preferentially located in early replicated regions and occupy distinct clusters in the nucleus. However, our data suggest that, in general, nuclear position of TPGs in hematological cancers explains neither TPG pairing nor clinical frequency. Taken together, our results support a model in which genomic features related to regulation of expression and replication timing determine the set of candidate genes more likely to be translocated in hematological tissues, with functional constraints being responsible for specific gene combinations.
Asunto(s)
Genes Relacionados con las Neoplasias , Genómica , Neoplasias Hematológicas/genética , Translocación Genética , Regiones no Traducidas 3' , Perfilación de la Expresión Génica , HumanosRESUMEN
BACKGROUND: Approximately one-third of diffuse large B cell lymphoma (DLBCL) patients exhibit co-expression of MYC and BCL2 (double-expressor lymphoma, DEL) and have a dismal prognosis. Targeted inhibition of the anti-apoptotic protein BCL2 with venetoclax (ABT-199) has been approved in multiple B-cell malignancies and is currently being investigated in clinical trials for DLBCL. Whether BCL2 anti-apoptotic function represents a multifaceted vulnerability for DEL-DLBCL, affecting both lymphoma B cells and T cells within the tumor microenvironment, remains to be elucidated. METHODS: Here, we present novel genetically engineered mice that preclinically recapitulate DEL-DLBCL lymphomagenesis, and evaluate their sensitivity ex vivo and in vivo to the promising combination of venetoclax with anti-CD20-based standard immunotherapy. RESULTS: Venetoclax treatment demonstrated specific killing of MYC+/BCL2+ lymphoma cells by licensing their intrinsically primed apoptosis, and showed previously unrecognized immunomodulatory activity by specifically enriching antigen-activated effector CD8 T cells infiltrating the tumors. Whereas DEL-DLBCL mice were refractory to venetoclax alone, inhibition of BCL2 significantly extended overall survival of mice that were simultaneously treated with a murine surrogate for anti-CD20 rituximab. CONCLUSIONS: These results suggest that the combination of anti-CD20-based immunotherapy and BCL2 inhibition leads to cooperative immunomodulatory effects and improved preclinical responses, which may offer promising therapeutic opportunities for DEL-DLBCL patients.
Asunto(s)
Compuestos Bicíclicos Heterocíclicos con Puentes , Inmunoterapia , Linfoma de Células B Grandes Difuso , Animales , Ratones , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/uso terapéutico , Modelos Animales de Enfermedad , Inmunoterapia/métodos , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Proteínas Proto-Oncogénicas c-bcl-2 , Microambiente Tumoral , Proteínas Proto-Oncogénicas c-mycRESUMEN
Acute myeloid leukemias (AMLs) result from multiple genetic alterations in hematopoietic stem cells. We describe a novel t(12;18)(p13;q12) involving ETV6 in a patient with AML. The translocation resulted in overexpression of SETBP1 (18q12), located close to the breakpoint. Overexpression of SETBP1 through retroviral insertion has been reported to confer growth advantage in hematopoietic progenitor cells. We show that SETBP1 overexpression protects SET from protease cleavage, increasing the amount of full-length SET protein and leading to the formation of a SETBP1-SET-PP2A complex that results in PP2A inhibition, promoting proliferation of the leukemic cells. The prevalence of SETBP1 overexpression in AML at diagnosis (n = 192) was 27.6% and was associated with unfavorable cytogenetic prognostic group, monosomy 7, and EVI1 overexpression (P < .01). Patients with SETBP1 overexpression had a significantly shorter overall survival, and the prognosis impact was remarkably poor in patients older than 60 years in both overall survival (P = .015) and event-free survival (P = .015). In summary, our data show a novel leukemogenic mechanism through SETBP1 overexpression; moreover, multivariate analysis confirms the negative prognostic impact of SETBP1 overexpression in AML, especially in elderly patients, where it could be used as a predictive factor in any future clinical trials with PP2A activators.
Asunto(s)
Proteínas Portadoras/genética , Transformación Celular Neoplásica/genética , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/genética , Proteínas Nucleares/genética , Anciano , Secuencia de Aminoácidos , Secuencia de Bases , Células Cultivadas , Regulación Leucémica de la Expresión Génica , Humanos , Células K562 , Masculino , Datos de Secuencia Molecular , Pronóstico , Regulación hacia ArribaRESUMEN
In this article, we show that introns harboring translocation breakpoints in tumors are significantly longer than non-translocated introns of the same genes but are not enriched significantly in sequence elements potentially involved in chromosomal rearrangements. Our findings provide evidence that double-strand breaks, the type of DNA damage that leads to translocations in tumors, are created at random points in the genome, and that sequence elements do not have a widespread role in the localization of these breaks.
Asunto(s)
Daño del ADN/genética , ADN/genética , Neoplasias/genética , Translocación Genética , Rotura Cromosómica , Genoma Humano , Humanos , Intrones , Distribución AleatoriaRESUMEN
BACKGROUND: Despite the importance of chromosomal translocations in the initiation and/or progression of cancer, a comprehensive catalog of translocation breakpoints in which these are precisely located on the reference sequence of the human genome is not available at present. DESCRIPTION: We have created a database that describes the genomic location of 1,225 translocation breakpoints in human tumors, corresponding to 247 different genes, using information from publicly available sources. Junction sequences from reciprocal translocations were obtained from 655 different references (either from the literature or from nucleotide databases), and were mapped onto the reference sequence of the human genome using BLAST. All translocation breakpoints were thus referred to precise nucleotide positions (949 breakpoints) or gene fragments (introns or exons, 276 breakpoints) within specific Ensembl transcripts. CONCLUSION: TICdb is a comprehensive collection of finely mapped translocation breakpoints, freely available at http://www.unav.es/genetica/TICdb/. It should facilitate the analysis of sequences encompassing translocation breakpoints and the identification of factors driving translocation events in human tumors.
Asunto(s)
Sitios Frágiles del Cromosoma , Neoplasias/genética , Translocación Genética , Secuencia de Bases , Genoma Humano , Humanos , Datos de Secuencia Molecular , ARN Mensajero/genéticaRESUMEN
We describe a new PDGFRB fusion associated with a t(5;14)(q33;q24) in a patient with a longstanding chronic myeloproliferative disorder with eosinophilia. After confirmation of PDGFRB involvement and definition of the chromosome 14 breakpoint by fluorescence in situ hybridization, candidate partner genes were selected on the basis of the presence of predicted oligomerization domains believed to be an essential feature of tyrosine kinase fusion proteins. We demonstrate that the t(5;14) fuses PDGFRB to NIN, a gene encoding a centrosomal protein with CEP110-like function. After treatment with imatinib, the patient achieved hematological and cytogenetical remission, but NIN-PDGFRB mRNA remained detectable by reverse transcription-PCR.
Asunto(s)
Antineoplásicos/uso terapéutico , Trastornos Mieloproliferativos/tratamiento farmacológico , Trastornos Mieloproliferativos/genética , Proteínas de Fusión Oncogénica/genética , Piperazinas/uso terapéutico , Pirimidinas/uso terapéutico , Proteínas Tirosina Quinasas Receptoras/genética , Receptor beta de Factor de Crecimiento Derivado de Plaquetas/genética , Adulto , Secuencia de Bases , Benzamidas , Cromosomas Humanos Par 14/genética , Cromosomas Humanos Par 5/genética , Reordenamiento Génico , Humanos , Mesilato de Imatinib , Hibridación Fluorescente in Situ , Masculino , Datos de Secuencia Molecular , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Translocación GenéticaRESUMEN
It has been shown that methylation of CpG dinucleotides located in the promoter region of TP53 is associated with low expression levels of this gene. We have analysed the methylation status of one CpG dinucleotide and of three CCWGG motifs, also located in the promoter region of the gene, in bone marrow samples obtained from patients with acute lymphoblastic leukemia (ALL). Eight out of 25 samples analysed showed methylation of either the CpG dinucleotide, the CCWGG motifs or both. Relative to nonmethylated leukemia samples, TP53 expression levels were decreased in all methylated samples in which TP53 expression could be measured. Methylation of CpG and CCWGG motifs in the promoter of TP53 could represent a novel mechanism leading to functional impairment of this tumor suppressor gene in ALL.
Asunto(s)
Islas de CpG , Metilación de ADN , Regulación Leucémica de la Expresión Génica/genética , Silenciador del Gen , Genes p53 , Proteínas de Neoplasias/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Regiones Promotoras Genéticas/genética , Elementos Silenciadores Transcripcionales , Médula Ósea/patología , ADN de Neoplasias/genética , Humanos , Proteínas de Neoplasias/biosíntesis , Leucemia-Linfoma Linfoblástico de Células Precursoras/clasificación , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Proteína p53 Supresora de Tumor/biosíntesisRESUMEN
We have prepared and characterised injectable adenovirus-loaded polymeric microparticles to be used for in vitro and in vivo gene transfer studies. Microparticles were prepared by the water-in-oil-in-water solvent evaporation method using a novel system where the emulsification process is carried out by the turbulent injection of the phases in the total recirculation one-machine system (TROMS) apparatus. In vitro studies were performed to assess the amount of infectious adenovirus released from the microparticles, showing that these microparticles release higher amounts of infectious adenovirus than microparticles prepared by standard emulsification techniques. We also tested whether sustained release in vivo could overcome the short-lived gene expression profile which is typical of adenovirus delivery into muscle. Intramuscular injection of adenovirus-loaded microparticles in immunocompetent mice showed transgene (beta-galactosidase) expression for at least 7 weeks in two out of four muscles injected with adenovirus-loaded microparticles prepared by TROMS, but not in control muscles injected with purified adenovirus stocks.
Asunto(s)
Adenoviridae/genética , Ácido Láctico/síntesis química , Microesferas , Ácido Poliglicólico/síntesis química , Polímeros/síntesis química , Tecnología Farmacéutica/instrumentación , Tecnología Farmacéutica/métodos , Adenoviridae/metabolismo , Animales , Preparaciones de Acción Retardada/síntesis química , Preparaciones de Acción Retardada/farmacocinética , Femenino , Vectores Genéticos , Células HeLa , Humanos , Ácido Láctico/farmacocinética , Ratones , Ratones Endogámicos BALB C , Ácido Poliglicólico/farmacocinética , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros/farmacocinética , Transducción GenéticaRESUMEN
When studying mutations in DNA samples, determining whether novel sequence changes are somatic mutations or germline polymorphisms can be difficult. Here we describe a novel and very simple approach for identification of somatic mutations and loss of heterozygosity (LoH) events in DNA samples where no matched tissue sample is available. Our method makes use of heterozygous polymorphisms that are located near the putative mutation to trace both germinal alleles.
Asunto(s)
Análisis Mutacional de ADN/métodos , ADN/genética , Mutación , Neoplasias/genética , Alelos , Humanos , Pérdida de Heterocigocidad , Polimorfismo GenéticoAsunto(s)
Metilación de ADN , Neoplasias Hematológicas/genética , Proteínas Supresoras de la Señalización de Citocinas/genética , Islas de CpG , Proteínas de Fusión bcr-abl/genética , Humanos , Janus Quinasa 2/genética , Células Mieloides/patología , Mutación Puntual , Proteína 1 Supresora de la Señalización de Citocinas , Proteína 3 Supresora de la Señalización de CitocinasRESUMEN
A search for genes potentially regulated by STAT5 identified leukemia inhibitory factor (LIF) as a good candidate. Using various experimental approaches, we have validated LIF as a direct transcriptional target of STAT5 in myeloid cell lines: STAT5 binds to LIF promoter, and LIF expression is increased after activation of the JAK2/STAT5 pathway. We also found that LIF expression is significantly increased in patients with chronic myeloproliferative neoplasms with and without activating mutations of the pathway, indicating that LIF might play an important role in STAT5-mediated oncogenesis.
RESUMEN
Hematological malignancies with eosinophilia are often associated with fusions in PDGFRA, PDGFRB, or FGFR1 genes. RT-PCR has proved to be useful for finding new PDGFRA gene fusions, but some studies have shown overexpression of the TK domain which cannot be explained by the existence of such aberrations. This fact could be related to the expression of alternative PDGFRA transcripts. We show that quantification of the expression of three different PDGFRA fragments discriminates between PDGFRA alternative transcripts and fusion genes, and we have tested this novel methodological approach in a group of eosinophilia cases. Our data show that alternative PDGFRA transcripts should be taken into account when screening for PDGFRA aberrations, such as gene fusions, by RT-PCR. Expression from an internal PDGFRA promoter seems to be a frequent event, in both normal and leukemic samples, and is probably related to physiological conditions, but it could have a role in other tumors. Even so, we show that our RQ-PCR methodology can discriminate expression of alternative transcripts from the presence of X-PDGFRA fusion genes.
Asunto(s)
Empalme Alternativo/genética , Eosinofilia/genética , Regulación Neoplásica de la Expresión Génica , Neoplasias Hematológicas/genética , Proteínas de Fusión Oncogénica/genética , Receptor alfa de Factor de Crecimiento Derivado de Plaquetas/genética , Estudios de Casos y Controles , Línea Celular Tumoral , Eosinofilia/etiología , Eosinofilia/patología , Femenino , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/patología , Humanos , Hibridación Fluorescente in Situ , Masculino , Pronóstico , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
BCR/ABL1-negative chronic myeloproliferative neoplasms (CMPNs) are a heterogeneous group of clonal hematological malignancies. Over recent years, some genetic events in tyrosine kinase (TK) genes have been described as causal events of these diseases. To identify new genetic aberrations underlying these diseases, we used denaturing high performance liquid chromatography and fluorescence in situ hybridization (FISH) to analyze 17 genes from two receptor-TK families (III and IV) and from three cytoplasmic-TK families (Syk, Abl, and Jak) on samples from 44 BCR/ABL1-negative and JAK2(V617F)-negative CMPN patients with different clinical phenotypes. Although screening by FISH did not reveal novel chromosomal aberrations, several sequence changes were detected. None of them were frequent events, but we identified a new potential activating mutation in the FERM domain of JAK2(R340Q). None of the germline JAK2(V617F) single-nucleotide polymorphisms detected differed in distribution between patients and control subjects. In summary, data presented here show that these genes are not frequently mutated or rearranged in CMPNs, suggesting that molecular events causing these disorders must be located in other genes.
Asunto(s)
Proteínas de Fusión bcr-abl/metabolismo , Janus Quinasa 2/química , Janus Quinasa 2/genética , Mutación/genética , Trastornos Mieloproliferativos/enzimología , Trastornos Mieloproliferativos/genética , Oncogenes/genética , Secuencia de Aminoácidos , Secuencia de Bases , Estudios de Casos y Controles , Enfermedad Crónica , Exones/genética , Femenino , Predisposición Genética a la Enfermedad , Pruebas Genéticas , Humanos , Hibridación Fluorescente in Situ , Masculino , Datos de Secuencia Molecular , Polimorfismo de Nucleótido Simple/genética , Estructura Terciaria de ProteínaAsunto(s)
Antineoplásicos Fitogénicos/efectos adversos , Cromosomas Humanos Par 16/genética , Cromosomas Humanos Par 8/genética , Leucemia Monocítica Aguda/terapia , Proteínas de Fusión Oncogénica/genética , Podofilotoxina/efectos adversos , Translocación Genética/genética , Adulto , Trasplante de Médula Ósea , Bandeo Cromosómico , Humanos , Hibridación Fluorescente in Situ , Cariotipificación , Leucemia Monocítica Aguda/inducido químicamente , Leucemia Monocítica Aguda/genética , Masculino , Inducción de RemisiónRESUMEN
BACKGROUND: The recurrence and non-random distribution of translocation breakpoints in human tumors are usually attributed to local sequence features present in the vicinity of the breakpoints. However, it has also been suggested that functional constraints might contribute to delimit the position of translocation breakpoints within the genes involved, but a quantitative analysis of such contribution has been lacking. METHODOLOGY: We have analyzed two well-known signatures of functional selection, such as reading-frame compatibility and non-random combinations of protein domains, on an extensive dataset of fusion proteins resulting from chromosomal translocations in cancer. CONCLUSIONS: Our data provide strong experimental support for the concept that the position of translocation breakpoints in the genome of cancer cells is determined, to a large extent, by the need to combine certain protein domains and to keep an intact reading frame in fusion transcripts. Additionally, the information that we have assembled affords a global view of the oncogenic mechanisms and domain architectures that are used by fusion proteins. This can be used to assess the functional impact of novel chromosomal translocations and to predict the position of breakpoints in the genes involved.
Asunto(s)
Neoplasias/genética , Proteínas de Fusión Oncogénica/genética , ARN Mensajero/genética , Translocación Genética , Humanos , Sistemas de Lectura AbiertaAsunto(s)
Proteínas de Unión al ADN/genética , Leucemia Mieloide Aguda/genética , Leucemia Mielomonocítica Crónica/genética , Mutación , Proteínas Proto-Oncogénicas/genética , Edad de Inicio , Dioxigenasas , Frecuencia de los Genes , Humanos , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/epidemiología , Leucemia Mielomonocítica Crónica/diagnóstico , Leucemia Mielomonocítica Crónica/epidemiología , Mutación/fisiología , Síndromes Mielodisplásicos/epidemiología , Síndromes Mielodisplásicos/genética , Trastornos Mieloproliferativos/epidemiología , Trastornos Mieloproliferativos/genéticaRESUMEN
Rearrangements in the distal region of the short arm of chromosome 1 are recurrent aberrations in a broad spectrum of human neoplasias. However, neither the location of the breakpoints (BP) on 1p36 nor the candidate genes have been fully determined. We have characterized, by fluorescence in situ hybridization (FISH), the BP in 26 patients with hematological neoplasias and 1p36 rearrangements in the G-banding karyotype. FISH allowed a better characterization of all samples analyzed. Nine cases (35%) showed reciprocal translocations, 15 (58%) unbalanced rearrangements, and two (7%) deletions. We describe two new recurrent aberrations. In 18 of the 26 cases analyzed the BP were located in band 1p36, which is 25.5 Mb long. In 14 of these 18 cases (78%) and without distinction between myeloid and lymphoid neoplasias, the BP clustered in a 2.5 Mb region located between 1p36.32 and the telomere. Interestingly, this region is contained in the 10.5 Mb cluster on 1p36.22-1pter defined in cases with 1p36 deletion syndrome. The 2.5 Mb region, located on 1p36.32-1pter, has a higher frequency of occurrence of tandem repeats and segmental duplications larger than 1 kb, when compared with the 25.5 Mb of the complete 1p36 band. This could explain its proneness for involvement in chromosomal rearrangements in hematological neoplasias.